Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Comparative analysis of the immunogenicity of SARS-CoV nucleocapsid DNA vaccine administrated with different routes in mouse model

Hui Hu a, b, Xianqing Huang b, Ling Tao a, Yi Huang a, Bao-an Cui b, *, Hanzhong Wang a, **

a State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Science, Wuhan 430071, PR China
b College of Animal Science and Veterinary Medicine, Henan Agricultural University, Zhengzhou, Henan 450002, PR China

1. Introduction

Severe acute respiratory syndrome (SARS) is a new emerging infectious disease that led to thousands of human infections and hundreds of deaths in the year of 2002–2004. The causative agent of SARS was identified as a novel coronavirus, named as SARS-CoV [1–5]. SARS-CoV is phylogenetically different from other members of the coronaviridae family and is the only coronavirus currently known to cause severe morbidity and mortality in humans [6,7]. Although the SARS epidemic was successfully contained in July 2003, the pathogenesis of SARS-CoV remains poorly understood and there is no effective treatment for SARS currently. Prevention through contact-reduction or transmission-blocking measures has been the important means available to modify the devastating impact of this illness. Prevention through vaccination would be an attractive alternative that is less reliant on individual case detection to be effective.

SARS-CoV genome contains four major structure proteins including the spike (S), envelope (E), membrane (M), and nucleocapsid (N) [6–8]. The N protein in many coronaviruses is highly immunogenic and abundantly expressed during infection [9–12]. N protein of the feline infectious peritonitis virus (FIPV) has been used as subunit vaccines to induce protective immunity and to prevent the progression of diseases in a cat model [13]. In porcine coronavirus, transmissible gastroenteritis virus (TGEV), the N protein is a representative antigen for the T cell response and may induce both cellular and humoral immune response [14]. These results indicate that a good N protein vaccine candidate should elicit strong immune responses. The SARS-CoV N protein is highly conserved (99%) within different isolates, and shares 20–30% amino acid homology with the N proteins of other coronaviruses [7]. Thus, the N protein is an important target for SARS-CoV vaccine development.

The immunogenicity of SARS-CoV N protein has been under investigation for a long time. Antibodies against the N protein are longer lived and occur in greater abundance in SARS patients than antibodies against other viral components such as the S, M and E proteins [15–21]. In previous study, N protein is a representative antigen for the T cell response in vaccine setting [22], and the mice vaccinated with calreticulin (CRT)/N DNA were capable of significantly reducing the titer of challenging vaccinia virus expressing the N protein of SARS virus [23]. It has been reported that N DNA vaccine could induce SARS-specific T cell proliferation and cytotoxic T cells...
activity, further experiments demonstrate that SARS-N administra-
tion could induce virus-specific cellular responses in human cells
using SCID-PBL/humouse model [24,25]. Therefore, based on these
observations, we initially focused on the SARS-CoV N protein as the
target antigen for our DNA vaccine development.

It has been reported that DNA vaccination is a practical and
effective way to induce humoral and cellular immune responses
and has shown great promise for protective immune responses
against several diseases in experimental animal models including
HIV, tuberculosis and malaria [26,27]. Several routes and meth-
ods of DNA immunization have been shown to generate Ab, Th
cells, and CTL responses. Apart from the conventional intramuscular
immunization, recent experiments have demonstrated that electro-
poration can greatly enhance plasmid vaccination, and is associated
with increased levels of gene expression. Additionally, electropo-
ration displays an adjuvant quality to increased gene expression
[28,29]. Another convenient DNA vaccine delivery system is oral
vaccination using live-attenuated *Salmonella typhimurium* [30,31].
The use of attenuated strains of *Salmonella* as vehicles to deliver
plasmid DNA in vivo is an effective method to induce strong
cell-mediated and humoral immune responses at mucosal sites
[31–35]. Thus, we were particularly interested in electroporation
immunization and oral immunization with live-attenuated *S.
typhimurium* in vivo. Few studies have directly compared the
immune responses generated by different vaccination means of
SARS-CoV DNA immunization. So in this study, the immunogenic-
tivities of SARS-CoV nucleocapsid DNA vaccination delivered
intramuscularly, by electroporation, and orally with live-attenuated
*S. typhimurium*, were compared in a mouse model.

2. Materials and methods

2.1. Plasmid DNA construct and bacterial strains

The mammalian expression vector pcDNA3.1(+)(Invitrogen,
Carlsbad, Calif.) was used for DNA vaccine studies in current experi-
ment. For the generation of recombinant plasmid pcDNA-N, the
DNA fragment encoding SARS-CoV nucleocapsid was amplified
with PCR from the cDNA of SARS-CoV W-20 strain.

The primers are as follows: 5′-GCA GGT ACC ATG TCT GAT AAT
GGA CCC CAA-3′; 5′-GGG AGA TCT TTA TGC CTT GAT TGA ATC AGC-3′.

The accuracy of the construct was confirmed by restriction diges-
tion and sequencing. The recombinant plasmid was amplified in
*Escherichia coli* DH5α and purified using Qiagen MegaPrep columns
(Qiagen). The purified plasmid was dissolved in endotoxin-free PBS
to a final concentration of 2 µg/µl and stored at −20 °C.

The attenuated *S. typhimurium* strain CS022 (ATCC 14028:
phop3) was kindly provided by Prof. GUO Ai-zhen (Huazhong Agri-
cultural University, School of Animal Medicine, Wuhan, P.R.),
and used as a carrier for oral genetic immunization.

2.2. Expression of the recombinant plasmids in vitro

The expression of the recombinant N protein in mammalian
cells in vitro was analyzed in 293 cells. Transfection was car-
rried out with Lipofectin reagent according to the procedure
described by the manufacturer (GIBCO BRL, Gaithersburg, MD).
In brief, a six-well tissue culture plate was seeded with 2 × 10^5
cells in 2 ml of Dulbecco’s modified Eagle’s medium (DMEM)
(GIBCO Invitrogen) supplemented with fetal bovine serum (FBS)
(GIBCO Invitrogen). The cells were incubated at 37 °C in 5%
CO_{2} until the culture was 60–80% confluent. 2 µg of the puri-
fied recombinant plasmid and 10 µl of Lipofectin reagent were
mixed with 100 µl FBS free medium, respectively, and incu-
bated for 30 min at room temperature. After incubation, 800 µl
of FBS free DMEM was added and the entire mixture was over-
laid onto 293 cells, and incubated for 6h at 37 °C. The mixture
was then replaced with 2 ml of DMEM containing 2% FBS and
incubated until examination. Cells were harvested for Western
blot analysis at 48 h after transfection. For Western blot analy-
sis, cell lysates were loaded onto a 10% polyacrylamide gel and
transferred onto polyvinylidene fluoride (PVDF) membrane (Amer-
sham), then stained using a rat anti-N antibody as the primary
antibody.

2.3. Animals and immunization

Eight-week-old female BALB/c mice were purchased from the
Center of Experimental Animal of Hubei Medical College, and ran-
donically divided into six groups (8 animals per group). Animals were
provided with pathogen-free water and food. Mice were immu-
nized three times at 2-week intervals intramuscularly (i.m.), by
electroporation or orally with *S. typhimurium*.

For the intramuscularly vaccinated group, the immunization
dose was 100 µg plasmid per animal by injecting the quadriceps
muscles. For electroporation immunization, animals were anest-
hetized and injected with 30 µg pcDNA-N plasmid intramuscularly
in the rear thighs. Two-needle array electrodes were inserted into
the muscles immediately after the injection of DNA by electropora-
tion. In vivo electroporation was performed with a BTX 820 square
wave generator (BTX, San Diego, CA), and the parameters were:
20 V/mm distance between the electrodes, 50-ms pulse length,
6 pulses with reversal of polarity after 3 pulses. For oral immu-
nization, the attenuated *Salmonella* strain CS022 harboring the
pcDNA-N DNA vaccine was cultured and grown to reach an OD_{600}
of 1.0. Cells were harvested by centrifugation, and resuspended at
the highest required density in phosphate-buffered saline (PBS, Sigma).

The inoculum of *S. typhimurium* was diluted to the appropriate con-
centration with 0.1 ml 10% sodium bicarbonate (NaHCO_{3}) buffer.
Each mouse was immunized by oral gavage with 5 × 10^9 CFU *S.
typhimurium* transformed with pcDNA-N. DNA dosage and CFU of
the attenuated *S. typhimurium* used in the immunized groups were
optimized by a series of preliminary experiments.

2.4. Analysis of the humoral immune response

Mice from each group were bled on days 0, 14, 28, 42 and
56. The blood was isolated and stored at −70 °C before antibody
measurement. Anti-N antibody levels in serum were assessed by
enzyme-linked immunosorbent assay (ELISA). N protein expressed
in *E. coli* was used as the detection antigen. pMAL-c2X vector (New
England Biolabs) was used to express the N protein in *E. coli*, which
expressed as a fusion protein (including a maltose-binding protein,
MBP). The N protein was purified through amylose columns
according to the manufacturer’s instructions (New England Bio-
labs). Optimized concentrations (5 µg/ml) of antigen were coated
onto 96-well plates (Costar) overnight at 4 °C. Plates were washed and
blocked with 1% BSA buffered solution for 1 h at 37 °C prior
to 2-h incubation with 1:100 diluted mouse sera at 37 °C. Bound
antibodies were detected with alkaline phosphatase-conjugated
goat anti-mouse IgG (Sigma). Color was developed by adding para-
nitrophenyl phosphate (pNPP) substrate, and absorbance was read
at 410 nm using a plate reader (Bio-RAD, USA). The values obtained
for mouse sera from the experimental groups were considered pos-
itive when they were >2.1 times of that of the control group. Values
<0.05 were not included. A similar ELISA protocol was followed to assess N-specific
immunoglobulin IgG and its subclasses (IgG1 and IgG2a). Horseradish peroxidase (HRP)-conjugated
goat anti-mouse IgG, IgG1, and IgG2a (Sigma) were used as secondary antibodies. Optical
density (OD) was read at 490 nm (A_{490}).
2.5. Lymphocyte proliferation assay (LPA)

The antigen-specific T cell proliferation (LPA) assay was performed as described previously [36]. In brief, 10 days following the final injection, mice were sacrificed and single-cell suspensions were prepared from the spleens for each group. Splenocytes (2 × 10^5 per well) in RPMI-1640 medium (Sigma) supplemented with 10% FBS were seeded in 96-well plates, in triplicates. Cultures were stimulated under the following various conditions for 60 h at 37 °C and 5% CO_2: 5 μg/ml Concanavalin A (positive control), 5 μg/ml purified N protein (specific antigen), 5 μg/ml Bovine serum albumin (irrelevant antigen), or medium alone (negative control). CellTiter 96 Aqueous One Solution Reagent (20 μl, Promega, USA) was added into each well according to the manufacturer’s protocols. Following 4-h incubation at 37 °C, absorbance was read at 490 nm. Proliferative activity was estimated using the stimulation index (SI) calculated from the mean OD_{490} of antigen-containing wells divided by the mean OD_{490} of wells without the antigen.

2.6. SARS-CoV N-specific ELISPOT assay

Cellular immune responses to N protein were assessed by IFN-γ and IL-4 ELISPOT assays using mouse splenocytes. Assays were performed according to the instruction manual (U-CyTech, Netherlands). Ninety-six-well plates were coated with 5 μg/ml rat anti-mouse IFN-γ or IL-4 (100 μl/well) in PBS, overnight. Plates were then washed three times with PBS containing 0.25% Tween-20, and blocked with PBS containing 5% FBS for 2 h at 37 °C. After three other washes with PBS containing 0.25% Tween-20, 1 × 10^5 splenocytes in 100 μl reaction buffer containing 2 μg/ml purified N-protein were added into each well. Plates were incubated for 16 h at 37 °C at 5% CO_2, and then washed 10 times with PBS. Biotinylated anti-mouse IFN-γ or IL-4 mAb at 1:500 dilutions was added for an additional hour incubation at room temperature. Following five washes with PBS, individual IFN-γ or IL-4 plates were developed as dark spots after a 10-min reaction with the peroxidase substrate AEC. Reactions were stopped by rinsing plates with demineralized water. Plates were air-dried at room temperature, and absorbance was read using an ELISPOT reader (Hitech Instruments). Spot-forming cells (SFC) per 10^6 splenocytes were calculated. The medium backgrounds were consistently <10 SFC per 10^6 splenocytes.

2.7. Statistical analysis

All data were presented as means ± S.D. for the immunized mice per group. The SPSS 13.0 software for windows was used for statistical analysis. Differences in humoral and cellular immune responses between groups were assessed by using single factor analysis of variances. The LSD t-test was used for between group comparisons. P-values <0.05 were considered statistically significant.

3. Results

3.1. In vitro expression of DNA constructs

The pcDNA-N construct was transiently transfected to 293 cells. The expression efficiency of N proteins was detected by Western blot. From the Western blot result we can see that a strong specific protein band for SARS-CoV N protein was detected (Lane 1 in Fig. 1). Cells transfected with pcDNA3.1 showed no cross-reaction with SARS-CoV N polyclone serum (Lane 2 in Fig. 1).

![Image](371x540 to 567x784)

**Fig. 1.** Analysis the recombinant SARS-CoV N protein expression in vitro by Western blot. The expression of SARS-CoV N protein was determined in 293 cells transfected with pcDNA-N, or pcDNA3.1(+) by Western blot analysis. Rat anti-N-specific antibody was used at a 1:10 dilution for the detection of N protein expression. Lane 1: lysate of 293T cells transfected with pcDNA-N; Lane 2: lysate of 293T cells transfected with pcDNA3.1(+); Lane 3: Protein molecular weight marker (Gibco).

3.2. Antibody responses to SARS-CoV N protein

After the expression of DNA construct was analyzed in vitro, BALB/c mice were inoculated in mice intramuscularly, by electroporation, or orally using attenuated *S. typhimurium* at 2-week intervals. To examine the humoral responses elicited by these different vaccinated routes, SARS-CoV N-specific antibodies were analyzed by indirect ELISA on sera samples collected 0, 14, 28, 42 and 56 days after the first immunization. It was found that the blood sera from pcDNA-N immunized groups could be strongly detected by N-specific protein, whereas blood sera collected from control groups inoculated with pcDNA 3.1, CS022, and PBS did not show any significant level of immune response (P<0.01) (Fig. 2). On day 14, the electroporation immunized group showed a detectable level of antibody, whereas the intramuscularly and oral immunized groups showed small quantities antibody. Large increases in immune antibodies were observed in the sera of immunization groups on day 42 (14 days after the second boost). On day 56, the electroporation immunized group showed a highest antibody level in all the immune groups (P<0.05). The specific antibodies in intramuscularly immunization groups were hold on a higher level too. However antibody level of the oral immunized group reduced slightly on day 56 after the first immunization. In all the immune process, the electroporation group immunized with pcDNA-N induced the highest level of antibody, while the oral immunization group evoked the lowest level of antibody among the three vaccination routes.

3.3. N-specific antibody subclasses

Ten days after the final immunization, N-specific antibody subclasses in mouse sera were determined by ELISA. As shown in Fig. 3, the anti-N protein IgG subtype profile revealed that both IgG1 and IgG2a were induced by all the immunization regimens. All three groups of control animals did not show any detectable-specific antibody response. The electroporation immunization group elicited a vigorous N-specific antibody response with predominantly IgG1.
Fig. 2. Antibody responses to SARS-CoV N protein induced by DNA vaccination with three different routes in mice. Animals were immunized intramuscularly (i.m.), by electroporation (i.e.), or orally using live-attenuated *Salmonella typhimurium* (oral). Serum samples (8 per group) were taken on days 0, 14, 28, 42 and 56 days after the first immunization.

subclass. IgG1 antibody level produced in the animals was over two times higher than IgG2a produced in this group (*P* < 0.05). The antibody response to the oral DNA vaccination induced a slightly weak antibody response compared with the other two immune routes, but it evoked a vigorous subclass IgG2a antibody level. The antibodies produced in the intramuscularly vaccinated animals were induced a higher level of the IgG2a and IgG1, the subclass IgG2a was appreciably higher than IgG1 in this group.

3.4. N-specific T cell proliferation

To study whether T cell proliferation could be influenced via the different immune routes, 10 days after final immunization, splenocytes obtained from the animals were cultured at concentration of 2 × 10^6 cells/ml in the presence of 5 μg/ml purified N protein for 60 h to analyze the antigen-induced T cell proliferation. The results showed that intramuscularly or by electroporation, as did the oral DNA vaccination, elicited a vigorous T cell proliferation response. As shown in Fig. 4, higher levels of lymphocytes stimulated by N protein were observed in mice immunized with pcDNA-N compared to controls (*P* < 0.05). Splenocyte proliferation in response to oral immunization group was high compared to the two other immunization routes. The intramuscularly immunized group induced a slightly stronger T cell response than the electroporation immunized group. These results indicate that immunizations with pcDNA-N elicit recognizable levels of antigen-specific T cell responses, and the oral immune routes evoke the strongest immune response.

3.5. ELISPOT assay for interferon-γ and Interleukin-4

ELISPOT assay was used to assess the magnitudes of N-specific IFN-γ (Th1) and IL-4 (Th2) T cell responses after mice were
vaccinated with N-DNA vaccine. Splenocytes from vaccinated mice were harvested 10 days after the final vaccination, N-specific IFN-γ and IL-4 ELISPOTs were enumerated. The protein dosage used for stimulation and the number of splenocytes were optimized to induce IFN-γ and IL-4 T cell responses (data not shown). ELISPOT background counts in wells containing splenocytes in the absence of mitogens or nominal antigens were no more than 10/10⁵ cells (data not shown).

As shown in Fig. 5A and B, only a low number of non-specific IFN-γ and IL-4 ELISPOTs were detected in the control groups. Significant numbers of N-specific IFN-γ and IL-4 ELISPOTs were detected in all the immunized groups (P < 0.01). The orally immunized group induced significantly higher levels of IFN-γ and IL-4-secreting compared with that induced by immunization with electroporation and intramuscularly immunized groups. Oral immunization in mice, which induced the lowest IgG level and main with electroporation and intramuscularly immunized groups. The intramuscularly immunized group evoked the lowest level of IFN-γ in all three routes. However, there was a clearly elevation of IL-4 in the electroporation vaccinated group over the intramuscularly group. The intramuscularly immunized group induced a slightly stronger IFN-γ, whereas a lower IL-4, than the electroporation immunized group. Moreover, in all groups, IFN-γ was induced to a much higher level than that of IL-4. These results suggest that N-DNA vaccine formulation is more immunogenic, and likely induces a stronger Th1 bias.

4. Discussion

Several vaccination routes of DNA vaccine have been shown to generate specific humoral and cellular responses [27,29,31,37]. However, few studies have directly compared the immune responses generated by different vaccination routes. In the present study, SARS-CoV N DNA vaccination approach was investigated utilizing three different immunization routes including intramuscularly, by electroporation, or orally carried by the live-attenuated S. typhimurium in mouse model. We clearly showed that the administration of the N DNA vaccine candidate with different immunization routes could induce a qualitatively different immune response profile.

In our former experiments we have shown that intramuscularly vaccination with SARS-CoV S DNA can elicit SARS-CoV S-specific humoral and cellular immune responses, and our results also suggest that these responses could be significantly enhanced by co-administrating an IL-2-expressing vector [38]. In our current study, utilizing SARS-CoV N-expressing plasmid, the immune responses produced by three different immune routes were compared too. Thus, the ability of the DNA immune strategy to enhance cellular and humoral immune responses has been confirmed in two distinct systems.

Our results showed that immunization intramuscularly induced a moderate T cell response and antibody response, predominant IgG2a compared to the other two immunized groups. Mice administrated by electroporation induced the highest antibody response (predominant IgG1) among the three immunization groups and a mid-level of cellular response. In contrast, the same DNA vaccine, when delivered orally with live-attenuated Salmonella, evoked vigorous T cell response, but a weak antibody production dominated by the IgG2a subclass. There results showed that the different vaccination routes generated the distinct types of immune responses. The antibody subclass and T cell responses style (IFN-γ and IL-4) did not change with further DNA immunizations by the same or the alternate doses of DNA used in the immune groups (data not shown). These indicate that the ability to generate different Th types was not due to differences in the doses of DNA used in DNA immunization. These findings have important implications for vaccine design and studies of the mechanism of Th cell differentiation.

DNA vaccines have attracting increased attention due to multiple advantages over conventional vaccines. Attempts to improve the vaccines immune effects focus on enhancing DNA delivery and employing novel immunoadjuvants [29,31,37]. Electroporation has emerged as an effective method for delivering DNA vaccines, significantly enhancing immune responses. Previously, some experiments have shown that electroporation improved the immunogenicity of DNA vaccines in mice, guinea pigs, rabbits, and rhesus macaques [39–41]. In this study, we observed the antigen-specific antibody level induced by electroporation vaccination was higher than that have been seen in other two DNA vaccination studies. This phenomenon could be explained as following: firstly, the application of short electrical pulses to the target tissue, renders the cell membrane transiently permeable to DNA and other molecules. Secondly, the muscle could be damage at the site where the electroporation took place. Although the damage observed is minor since very little of the muscle mass is affected, the damaged cells in electroporation will release of “danger signals” and attract antigen–presenting cells and other immune cells, which resulted in increased DNA uptake, leading to enhanced protein expression in treated muscle cells. Hence, the electroporation may work as an adjuvant to increase the immune response against the Ag produced. Another promising way is delivery by using attenuated Salmonella strains [34,42]. It has been shown repeatedly, and was supported by the results of this study, that a unique strong T cell response, but a relatively weak antibody response, was elicited by immunization with the live-attenuated S. typhimurium containing the DNA vaccine [33,35,43]. In the present study, we have also shown that a strong T cell proliferation response was associated with the administration of live-attenuated S. typhimurium containing the DNA vaccine. This strong T cell response was further supported by the detection of a high level of IFN-γ, a Th1-associated cytokine, in the supernatant of the splenocyte cultures derived from oral immunized mice. On the other hand, the antibody response induced by live-attenuated S. typhimurium carrying the DNA vaccine is relatively weak, but predominantly IgG2a. This is in contrast to the strong IgG response associated DNA vaccination by electroporation. Salmonella has the ability to accumulate where the immune response takes action (lymphatic nodes and spleen). Attenuated Salmonella cells can be effectively consumed by peripheral phagocyte cells, penetrate through the mucosa M-cells and migrate towards inductive sites of lymphoid organs tuning up the immune response [31,34,44]. Most of the N peptides might be cleared within the M cells, and presented through the MHCI pathway, giving rise to a strong cellular response. At the same time, a small amount of N peptides generated in the M cells might be secreted and presented by B cells through the MHC class II pathway, resulting in a poor antibody response.

It should be noted that the same DNA, when carried by different routes, induced different immune response profiles. This might be due to different ways of presentation of the N antigen by professional antigen-presenting cells (APC) through i.m., electroporation, or oral immunization. Our results show that the delivery of DNA vaccines by electroporation and orally using live-attenuated Salmonella in vivo is an effective method to increase expression in muscle tissues leading to marked improvement in immune responses. In addition, based on our observation that oral DNA vaccination induced a strong T cell-mediated immune response, whereas electroporation immunizations induced moderate T cell but vigorous antibody responses, further studies should be carried out using a combination strategy of both oral and electroporation immunizations, to stimulate higher cellular and humoral immune responses.
DNA vaccines hold promise for use in humans [27]. However, the immunogenicity of SARS-CoV DNA vaccine in humans has yet to be established. Whether this approach could be applied to other animal models is still unknown, and its immunogenicity in humans remains to be established. What’s more, for the SARS-CoV vaccine, there are significant limitations with current technologies that have prevented the full effectiveness of DNA vaccines in larger animals and humans because of the safety concerns about live virus. Therefore, it is very important to evaluate the efficacy of SARS DNA vaccine in any other animal models, which is a highly relevant translational model for demonstrating human immune responsiveness.

Acknowledgements

This work was supported in part by a National “973 Project” grant (2005CB523000) and “863 Project” grant (2005AA219070) from the Ministry of Science and Technology, People’s Republic of China and Chinese Academy of Sciences (KSCX1-YW-R07). We would like to thank Dr. Zhanyong Wei (College of Animal Science and Veterinary Medicine, Henan Agricultural University) for the scientific editing of the manuscript.

References

[1] Stadler K, Massignani V, Eickmann M, Becker S, Ahsbrignani S, Klenk HD, et al. SARS—beginning to understand a new virus. Nat Rev Microbiol 2001;3(3): 209–18.

[2] Foucher RA, Kuiken T, Schutten M, van Amerongen G, van Doornum GJ, van den Hoogen B, et al. Antimoniak: Koch’s postulates fulfills for SARS virus. Nature 2003;423(6937):240.

[3] Ksiazek TG, Erdman D, Goldsmith CS, Zaki SR, Peret T, Emery S, et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 2003;348(20):1976–93.

[4] Drosten C, Gunther S, Preiser W, van der Werf S, Brodt HR, Becker S, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 2003;348(20):1976–93.

[5] Peris JS, Lai ST, Poons LL, Guan Y, Yang L, Lim W, et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 2003;363(9396):1319–25.

[6] Marra MA, Jones SJ, Astell CR, Holt RA, Brooks-Wilson A, Butterfield YS, et al. The Genome sequence of the SARS-associated coronavirus. Science 2003;300(5624):1394–404.

[7] Rota PA, Osterheint MS, Morens SS, van Doornum GJ, van den Hoogen B, et al. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 2003;300(5624):1394–404.

[8] Christian MD, Poutanen SM, Loutfy MR, Muller MP, Low DE. Severe acute respiratory syndrome. Science 2003;300(5624):1394–404.

[9] Eickmann M, Becker S, Klenk HD, et al. SARS-coronavirus in BALB/c mice. Biochim Biophys Res Commun 2003;327(1):130–5.

[10] Tan YJ, Goh PY, Fielding BC, Shen C, Chou CF, Fu JL, et al. Profiles of antibody responses by severe acute respiratory syndrome coronavirus recombinant proteins and their potential use as diagnostic markers. Clin Diag Lab Immunol 2004;11(2):362–71.

[11] Timani KA, Ye L, Zhu Y, Wu Z, Gong Z. Cloning, sequencing, expression, and purification of SARS-associated coronavirus nucleoprotein for serodiagnosis of SARS. J Clin Virol 2004;30(4):309–12.

[12] Wang C, Yuan Z, Lin LC, Henghe HR, Chang YF. Immune responses with DNA vaccines encoded different gene fragments of severe acute respiratory syndrome coronavirus in BALB/c mice. Biochim Biophys Res Commun 2005;327(1):130–5.

[13] Cho W, Tamin A, Soloff A, Di-AIuto L, Nwanebu E, Robbins PD, et al. Effects of a SARS-associated coronavirus vaccine in monkeys. Lancet 2003;362(9399):1895–6.

[14] LeBlanc R, Vasquez Y, Hannaman D, Kumar N. Markedly enhanced immunogenicity of a PDUC DNA-based malaria protein—blocking vaccine by in vivo electroporation. Vaccine 2008;26(12):185–92.

[15] Scheerin LP, Karjal T, Tjelle TE, Presidente PJ, Mathiesen I, Newton SE. In vivo electroporation improves immune responses to DNA vaccine in sheep. Vaccine 2004;22(13–14):1820–5.

[16] Dougan G, Hormaeche CE, Maskell DJ. Live oral Salmonella vaccines: potential use of attenuated strains as carriers of heterologous antigens to the immune system. Parassite Immunol 1987;9(2):151–60.

[17] Ashby D, Leduc I, Lauzon W, Lee BC, Singhal N, Cameron DW. Attenuated Salmonella typhimurium SL3261 as a vaccine vector for recombinant antigen in rabbits. J Immunol Methods 2005;299(1–2):153–64.

[18] Benjacob LP, Hopkins S, Potts A, Kelly S, Kraehnenbuch JP, Curtiss R, et al. The nature of the attentive of Salmonella typhimurium strains expressing human papillomavirus type 16 virus-like particles determines the systemic and mucosal antibody responses in nasally immunized mice. Infect Immun 1999;67(7):3674–80.

[19] Hoogen B, et al. Aetiology: Koch’s postulates fulfilled for SARS virus. Nature 2003;423(6937):904–18.

[20] Dougan G, Hormaeche CE, Maskell DJ. Live oral Salmonella vaccines: potential use of attenuated strains as carriers of heterologous antigens to the immune system. Parassite Immunol 1987;9(2):151–60.

[21] De Rose R, Tennent J, McWaters P, Chaplin PJ, Wood PR, Kimpton W, et al. Efficacy of live-attenuated Salmonellae is an effective method to prevent Herpes simplex virus-2 induced disease in mice. Vaccine 2001;19(13–14):1772–82.

[22] Daiji A, zur Lage S, Garbe AI, Chakraborty T, Weiss S. Oral delivery of DNA vaccine using attenuated Salmonella as carrier vectpr. FEMS Immunol Microbiol 2000;27(7):341–9.

[23] Harrison JA, Villarreal-Ramos B, Bastrens P, Damoreo de Hormaeche R, Hormaeche CE. Correlates of protection induced by live Aro-Salmonella typhimurium vaccines in the mouse typhoid model. Immunology 1997;90(4):618–25.

[24] Hoogen BG, et al. Aetiology: Koch’s postulates fulfilled for SARS virus. Nature 2003;423(6937):904–18.

[25] Fio L, Tsimineretzis S, Baralle F. Oral transgene vaccine mediated by attenuated Salmonellae is an effective method to prevent Herpes simplex virus-2 induced disease in mice. Vaccine 2001;19(13–14):1772–82.

[26] De Rose R, Trotter JN, McWaters P, Chaplain PJ, Wood PR, Kimpton W, et al. Efficacy of DNA vaccination by different routes of immunisation in sheep. Vet Immunopathol 2002;90(1–2):55–63.

[27] Hu H, Lu X, Tao L, Bai B, Zhang Z, Chen Y, et al. Induction of specific immune responses by severe acute respiratory syndrome coronavirus spike DNA vaccine with or without interleukin-2 immunization using different vaccination routes in mice. Clin Vaccine Immunol 2007;14(7):904–901.

[28] Otten GR, Schaefer M, Doe B, Liu H, Megele JD, Donnelly J, et al. Potent immunogenicity of an HIV-1 gag-pol fusion DNA vaccine delivered by in vivo electroporation. Vaccine 2006;24(21):4503–9.

[29] Widera G, Austin M, Rabussay D, Geldbeck C, Barnett SW, Chen M, et al. Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. Immunol 2000;149(9):4035–40.

[30] Ottgen G, Schaefer M, Doe B, Liu H, Srivastava I, zur Megele JD, et al. Enhancement of DNA vaccine potency in rhesus macaques by electroporation. Vaccine 2004;22(19):2489–93.

[31] Xiang R, Lode HN, Zhao TH, Ruhemian JM, Dolman CS, Rodriguez E, et al. An autologous oral DNA vaccine protects against murine melanoma. Proc Natl Acad Sci USA 2000;97(10):5492–7.

[32] Woo PC, Wong LP, Zheng BY, Yuen KY. Unique immunogenicity of hepatitis B virus DNA vaccine presented by live-attenuated Salmonella typhimurium. Vaccine 2001;19(20–22):2945–54.

[33] Shata MT, Reitz Jr MS, Devico AL, Lewis GK, Hone DM. Mucosal and systemic HIV-1 Env-specific CD8(+) T-cells develop after intragastric vaccination with a Salmonella Env DNA vaccine vector. Vaccine 2001;20(3–4):623–9.